Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Grey

Showing results (191-200 of 256) with videos related to

Pageof 26
Sort By:
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 26, 2010
Prolonged antiresorptive activity of zoledronate: a randomized, controlled trialAndrew Grey, Mark Bolland, Diana Wattie, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 20, 2020
Representation of Women as Authors of Rheumatology Research ArticlesEkta Bagga, Sarah Stewart, Gregory D Gamble, et al.
Endocrinology|November 26, 2002
The phospholipids sphingosine-1-phosphate and lysophosphatidic acid prevent apoptosis in osteoblastic cells via a signaling pathway involving G(i) proteins and phosphatidylinositol-3 kinaseAndrew Grey, Qi Chen, Karen Callon, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 29, 2021
Bone Mineral Density and Bone Turnover 10 Years After a Single 5 mg Dose or Two 5-Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open-Label Extension of a Randomized Controlled TrialAndrew Grey, Mark J Bolland, Anne Horne, et al.
Clinical Endocrinology|April 20, 2012
Pioglitazone in acromegaly - an open-label, prospective studyDavid D W Kim, Jovina Goh, Zaven Panossian, et al.
The American Journal of Clinical Nutrition|July 25, 2014
Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysisJohn A Ford, Graeme S MacLennan, Alison Avenell, et al.
Annals of Clinical Biochemistry|January 25, 2025
Biochemical osteomalacia in adults undergoing vitamin D testing in the North-East of ScotlandAngus D Macleod, Mark J Bolland, Andrew Balfour, et al.
Leukemia & Lymphoma|January 3, 2013
Bone metabolism during long-term treatment with imatinibSusannah O'Sullivan, Anne Horne, Diana Wattie, et al.
Bonekey Reports|August 17, 2013
Subgroup analysis for the risk of cardiovascular disease with calcium supplementsLoretta T Radford, Mark J Bolland, Greg D Gamble, et al.
The Journal of Clinical Endocrinology and Metabolism|December 4, 2008
The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal womenAndrew Grey, Mark J Bolland, Diana Wattie, et al.
Pageof 26

Showing results (191-200 of 256) with videos related to

Sort By:
Pageof 26
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 26, 2010
Prolonged antiresorptive activity of zoledronate: a randomized, controlled trialAndrew Grey, Mark Bolland, Diana Wattie, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 20, 2020
Representation of Women as Authors of Rheumatology Research ArticlesEkta Bagga, Sarah Stewart, Gregory D Gamble, et al.
Endocrinology|November 26, 2002
The phospholipids sphingosine-1-phosphate and lysophosphatidic acid prevent apoptosis in osteoblastic cells via a signaling pathway involving G(i) proteins and phosphatidylinositol-3 kinaseAndrew Grey, Qi Chen, Karen Callon, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 29, 2021
Bone Mineral Density and Bone Turnover 10 Years After a Single 5 mg Dose or Two 5-Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open-Label Extension of a Randomized Controlled TrialAndrew Grey, Mark J Bolland, Anne Horne, et al.
Clinical Endocrinology|April 20, 2012
Pioglitazone in acromegaly - an open-label, prospective studyDavid D W Kim, Jovina Goh, Zaven Panossian, et al.
The American Journal of Clinical Nutrition|July 25, 2014
Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysisJohn A Ford, Graeme S MacLennan, Alison Avenell, et al.
Annals of Clinical Biochemistry|January 25, 2025
Biochemical osteomalacia in adults undergoing vitamin D testing in the North-East of ScotlandAngus D Macleod, Mark J Bolland, Andrew Balfour, et al.
Leukemia & Lymphoma|January 3, 2013
Bone metabolism during long-term treatment with imatinibSusannah O'Sullivan, Anne Horne, Diana Wattie, et al.
Bonekey Reports|August 17, 2013
Subgroup analysis for the risk of cardiovascular disease with calcium supplementsLoretta T Radford, Mark J Bolland, Greg D Gamble, et al.
The Journal of Clinical Endocrinology and Metabolism|December 4, 2008
The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal womenAndrew Grey, Mark J Bolland, Diana Wattie, et al.
Pageof 26